Back to Noidecs or All Bud/Flower

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This page was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Terpene Profile (Claimed Estimate)

MyrceneMajorHerbal/Musk166-168℃
OcimeneMajorHerbal/Sweet174-175℃
TerpinoleneMajorFloral/Herbal185℃

MedBud currently tracks 39 common terpenes.

Dosing Look-Up Table (Estimated)

0.01/g2/mg THC0.4/mg CBD
0.05/g10/mg THC2/mg CBD
0.1/g20/mg THC4/mg CBD
0.15/g30/mg THC6/mg CBD
0.2/g40/mg THC8/mg CBD
0.25/g50/mg THC10/mg CBD
0.3/g60/mg THC12/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
United Kingdom Noidecs
Designation
T20:C4
Cultivar/Strain
Moby Dick
Classification
Sativa Hybrid
Chemotype
Type I: High THC
Flower Provided
Trimmed Whole Flower
THC Potential Range (±10%)
18-22%
CBD Potential Range (±10%)
4%
Cultivated/Produced by
Israel BOL Pharma
Cultivated or Packaged in
Flag of Israel Israel
Irradiation
Gamma-Irradiated
Imported by
United Kingdom Eaststone
Imported as
Schedule II: Finished Product

Patient Repackaging Label (BETA)

Label for Repackaging Download Thermal Label
Size: 76mm x 38mm (or other 2:1 format label)

It is generally recommended to keep medication in original packaging, lawful possession of medication in other packaging will face increased scrutiny.

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Discontinued

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Dispensing Patient Pharmacies

  •  Logo
  •  Logo
  •  Logo
  •  Logo
  •  Logo
  •  Logo
  •  Logo
  •  Logo
  •  Logo

Project Twenty21

Available on T21, a research project offering participating patients several discounted medications:

About Moby Dick

MDKSativa Hybrid

Dinafem crossed two of their mother plants, a variety of Haze and a variety of White Widow.

Dinafem Seeds® Logo

Bred by Spanish Flag Dinafem Seeds®

Moby Dick is a Sativa-dominant strain. Its name reflects its massive yields, which reportedly can reach 1,500 grams per square meter. The THC concentration of this strain may be as high as 20%.

Moby Dick comes from the breeders at Dinafem who crossed two of their mother plants, a variety of Haze and a variety of White Widow. The strain has two phenotypes: one with Sativa-dominant characteristics that can reach up to twelve feet outdoors, while the other is a smaller, Indica-dominant phenotype, that is only seen about 35% of the time.

Information provided could come from a third-party source, and may not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

United Kingdom About Lyphe Group Ltd

Noidecs Logo

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com

  Information provided is partially community sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)